Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery

Jennifer L. Remus, PhD; Robert Dantzer, DVM, PhD

Laboratory of Neuroimmunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Correspondence: Jennifer Remus, PhD, Laboratory of Neuroimmunology, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd, Houston, TX (jremus@mdanderson.org).

Abstract

Inflammation and depression are closely inter-related; inflammation induces symptoms of depression and, conversely, depressed mood and stress favor an inflammatory phenotype. The mechanisms that mediate the ability of inflammation to induce symptoms of depression are intensively studied at the preclinical level. This review discusses how it has been possible to build animal models of inflammation-induced depression based on clinical data and to explore critical mechanisms downstream of inflammation. Namely, we focus on the ability of inflammation to increase the activity of the tryptophan-degrading enzyme, indoleamine 2,3 dioxygenase, which leads to the production of kynurenine and downstream neuroactive metabolites. By acting on glutamatergic neurotransmission, these neuroactive metabolites play a key role in the development of depression-like behaviors. An important outcome of the preclinical research on inflammation-induced depression is the identification of potential novel targets for antidepressant treatments, which include targeting the kynurenine system and production of downstream metabolites, altering transport of kynurenine into the brain, and modulating glutamatergic transmission.

Keywords: Depression, inflammation, glutamate, quinolinic acid, indoleamine 2,3-dioxygenase

Introduction

Activation of the immune system, through either infection or administration of cytokines, causes significant changes in eating, drinking, social, and sleeping behaviors in both rodents (Hart, 1987; O’Reilly et al., 1988; Crestani et al., 1991; Yirmiya, 1996) and humans (Capuron et al., 2002; Vollmer-Conna et al., 2004). Similar behavioral alterations are found in patients with depression. For example, depressed individuals have disturbed sleep patterns (Coble et al., 1979; Pigeon et al., 2004; Armitage, 2007), greater fatigue (Demyttenaere, 2005), fewer social interactions (George et al., 1989), and anhedonia (Pizzagalli et al., 2007; Sherdell et al., 2012). Indeed many of these behavioral alterations are diagnostic criteria for major depression as outlined by the DSM.

The relationship between depression and immunity has been researched for several decades. Initially depression was thought to be associated with a suppression in immunity (Schleifer et al., 1984). Investigators came to this conclusion after finding that blood lymphocytes of depressed individuals had an attenuated proliferative response when stimulated with mitogens (Schleifer et al., 1984; Kronfol et al., 1986; Kronfol and House, 1989). This was associated with reduced natural killer cell activity (Nerozzi et al., 1989). In addition, depressed patients were known to have elevated glucocorticoids, specifically cortisol (Carroll et al., 1976), and a dysfunctional stress feedback system (Carroll et al., 1968). Since glucocorticoids were well known to dampen immune responses (Crabtree et al., 1979), the immunosuppression found in depressed patients seemed logical and corresponded nicely with the endocrine abnormalities. Contrary to the suggestion that depression was immunosuppressive, Smith (1991) proposed the macrophage theory of depression that drew on research demonstrating...
interleukin (IL)-1 can lead to endocrine abnormalities and significantly alter behavior. In addition, inflammation was seen as a common link between depression and other diseases that were often comorbid with depression. In short, Smith’s theory proposed that in depressed patients activated macrophages produced cytokines, which lead to depression (Smith, 1991). Soon, evidence began accumulating that depressed patients were actually showing patterns of an activated inflammatory response. Depressed patients were reported to have an increase in leukocytes, monocytes, and other inflammatory factors, including prostaglandins (Ohishi et al., 1988; Maes et al., 1992) and increased NK cells (Seidel et al., 1996). Maes (1995) followed up with his own studies on inflammation and depression and described several ways that inflammation could influence depression, including decreased bioavailability of tryptophan for the synthesis of serotonin. During the same time, animal studies were documenting the relationship between inflammation and sickness behavior (Bluthe et al., 1991, 1992a, 1992b, 1994, 1995; Kent et al., 1992; Nadjar et al., 2005). In addition to reducing motor activity and food intake and increasing slow wave sleep, the cytokine inducers lipopolysaccharide (LPS) (Bluthe et al., 1992a), IL-1 (Kent et al., 1992), and tumor necrosis factor (TNF) (Bluthe et al., 1991, 1994) were found to decrease social interaction in rodents. Importantly, these effects were obtained whether LPS or cytokines were administered at the periphery or in the brain, indicating a possible central site of action for peripheral cytokines. Yirmiya (1996) first reported that endotoxin caused depressive-like behaviors in rodents that were sensitive to the effects of antidepressant drugs.

Since the macrophage theory was proposed, the last 2 decades have seen an abundant amount of investigation into the relationship between inflammation and depression at both the clinical and preclinical levels. Patients with depression are now reported to have elevated levels of inflammatory markers, including proinflammatory cytokines (Kim et al., 2008; Shelton and Claiborne, 2010), C-reactive protein (Danese et al., 2008; Vogelzangs et al., 2012; Morris et al., 2014), and myeloperoxidase (Vaccarino et al., 2008). Although some studies have reported negative results (Carpenter et al., 2004; Basterzi et al., 2005), several meta analyses support the association between depression and proinflammatory cytokines (Howren et al., 2009; Dowlati et al., 2010). Furthermore, the literature indicates that only specific subtypes of depression are associated with inflammation. For example, patients with atypical depression have an increase in plasma C-reactive protein (Hickman et al., 2014), proinflammatory cytokines (Lamers et al., 2013), and leukocyte numbers (Rothermundt et al., 2001) compared with healthy controls or patients with melancholic depression, although one report supports both melancholic and atypical patients having elevated biomarkers of inflammation (Karlovic et al., 2012). Interestingly, atypical depression is also characterized by symptoms of fatigue, hyposomnia, and lethargy (Gold and Chorousos, 2002), which match the known behavioral effects of cytokines. Although not all traits of atypical depression align well with sickness behaviors, including weight gain and hypovigilance, it is possible that these are due to mechanisms other than inflammation.

Rodent models of depression are also associated with elevated levels of inflammation in the periphery and brain (Grippo et al., 2005; Goshen et al., 2008; You et al., 2011). In addition, Koo and Duman (2008) and Goshen et al. (2008) have demonstrated that cytokine signaling is essential for the development of depressive-like behaviors in stress-based animal models of depression. Further animal research has demonstrated that antidepressants may have antiinflammatory effects (Tynan et al., 2012), and antiinflammatory drugs can prevent depressive-like behaviors (Kreisel et al., 2014). While a complete review of this literature is too large to be completed here, comprehensive reviews of the research on inflammation and depression can be found elsewhere (Felger and Lotrich, 2013; Furtado and Katzman, 2015; Lotrich, 2015; Yirmiya et al., 2015).

Importantly, a direct effect of immune stimulation on mood has been demonstrated in a clinical population. Capuron and Ravault (1999) report that cancer patients treated with interferon-alpha and/or IL-2 developed depressive-like symptoms, and this has been replicated by others (Bonaccorso et al., 2002; Kraus et al., 2002; Reichenberg et al., 2005). In addition, it has been highlighted that patients afflicted with disorders associated with inflammation, including diabetes, multiple sclerosis, and cardiac disease, show higher rates of depression. Physically ill patients with chronic inflammation have an improvement in mood when given treatments that target inflammatory cytokines, such as the TNF-antagonist infliximab (Tybring et al., 2006; Feldman et al., 2008). Furthermore, rodent studies have confirmed the direct relationship between immune activation and depression. For example, rodents administered proinflammatory cytokines show depressive-like behaviors, such as increased immobility in the forced swim and tail suspension tests and reduced sucrose preference (Brebnner et al., 1999; Makino et al., 2000; Dunn and Swiergiel, 2005; Wu and Lin, 2008).

Our research group has focused on understanding inflammation-induced depression and the downstream mechanisms. We have taken great care in developing an animal model of depression that is based on the clinical literature demonstrating that depression develops on a background of sickness behavior (Dantzer et al., 2008). This review will discuss the current state of research on inflammation-induced depression, what is known about the mechanisms, and possible novel targets for the treatment of inflammation-induced depression.

Inflammation-Induced Depression

Inflammation-induced depression can be studied using a variety of inflammatory agents, including LPS, the viral mimetic Poly I:C, and Bacillus Calmette-Guerin (BCG). Treated animals lose weight, eat and drink less, and decrease their motor activity for several hours to days, depending on the nature of the inflammatory agent and dose. These sickness behaviors correspond with elevations in proinflammatory cytokines at the periphery and in the brain (Lay et al., 2000; Parnet et al., 2002; André et al., 2008). In the LPS-induced model of depression, sickness behaviors will typically resolve within 24 hours, whereas BCG inoculation will result in sickness behavior lasting several days (O’Connor et al., 2009a). Interestingly, when sickness behaviors have resolved, the rodents display depressive-like behaviors (Figure 1 for schematic). For example, 24 hours after injection of LPS, when motor activity is back to normal and appetite present, treated animals show increased immobility in the forced swim test and tail suspension test as well as decreased sucrose preference (Freho et al., 2007; O’Connor et al., 2009c; Sulakhiya et al., 2016; Ge et al., 2015). Sickness and depressive behaviors depend on the initial inflammation, as antiinflammatory agents can attenuate both (Bluthe et al., 1992a; Nadjar et al., 2005; Henry et al., 2008; O’Connor et al., 2009c). Interferon-gamma is a crucial component in this model, as transgenic animals with deletion of its receptor do not show depressive-like behaviors (O’Connor et al., 2009b). Likewise, many laboratories have continued to demonstrate that a variety of antiinflammatory compounds abrogate or attenuate depressive-like behaviors using this model (Ferreira Mello et al., 2013; Ji et al., 2014; Ma et al., 2014; Wang et al., 2014; An et al.,
Anxiety and depression often appear together in the clinical population (Reichenberg et al., 2001; Kubera et al., 2013; Adzic et al., 2015; Guan et al., 2015), or combining it with chronic stress exposure (Elgarf et al., 2014) to study depression. The primary focus of this review is depressive behaviors, there is a growing literature demonstrating inflammation-induced increases in anxiety-like behaviors in rodents (Salazar et al., 2012; Bassi et al., 2012; Gibney et al., 2013; Baganz et al., 2015; Savignac et al., 2016; Sriram et al., 2016; Sulakhaiya et al., 2016) and humans (Grigoliet et al., 2011; Reichenberg et al., 2001; Lasselin et al., 2016). Sulakhaiya (2016) found that LPS-treated animals have an increase in anxiety-like behavior, as measured by the elevated plus maze. Here, the LPS-treated animals spent more time in the closed arms and a reduction in time spent in the open arms. However, the animals were tested only a few hours after LPS administration, probably still at the peak of the sickness response. Testing behavioral measures of anxiety shortly after LPS injection may confound the results, as the rodents will most likely be moving less due to sickness. However, some papers have demonstrated anxiety behaviors after sickness behaviors have resolved (Salazar et al., 2012; Gibney et al., 2013). Anxiety and depression often appear together in the clinical population (Brown et al., 2001), and modeling both of these symptoms together can both be beneficial and problematic. On one hand, the presence of both anxiety and depression could reflect a more relevant model of depression, but it is difficult to distinguish the contribution of anxiety to depressive behaviors and vice versa.

Healthy human subjects given an inflammatory agent, such as endotoxin or typhoid vaccination, show a significant reduction in mood and increased anxiety (Reichenberg et al., 2001; Wright et al., 2005; Eisenberger et al., 2009, 2010). The reduction in mood is correlated with plasma IL-6 levels (Brydon et al., 2008; Eisenberger et al., 2009) as is fatigue (Brydon et al., 2008). Interestingly, imaging studies found that typhoid vaccination alters neural activity of the cingulate cortex and its connections with other brain areas associated with mood (Harrison et al., 2009). Similarly, Eisenberger et al. (2010) found that endotoxin treatment decreases ventral striatum responding to reward, further supporting that inflammation can alter critical neural circuits involved in depression.

### Indoleamine 2,3 Deoxygenase

Insights about mechanisms downstream of inflammation have come from clinical studies that examined the effects of interferon-alpha on mood of cancer and hepatitis C virus-infected patients. In both groups, the development of depressive symptoms was associated with decreased circulating levels of tryptophan (Bonaccorso et al., 2002; Capuron et al., 2002). Furthermore, a significant correlation between variations in tryptophan levels and changes in depression scores was reported. Specifically, the greater the fall in tryptophan levels, the more severe the symptoms of depression as measured by the Montgomery and Asberg depression rating scale (Capuron et al., 2002).

The relationship between tryptophan, serotonin, and depression has a long history in psychiatry. Tryptophan is the precursor of serotonin, and because tryptophan hydroxylase is not saturated by its substrate, the bioavailability of tryptophan regulates the amount of serotonin formed in the brain. Rodents fed a low tryptophan-containing diet show a decrease in serotonin in their brain (Biggio et al., 1974). Similar, human subjects on a tryptophan-restricted diet have decreased levels of tryptophan and serotonin metabolites in their cerebrospinal fluid (Perez-cruet et al., 1974). Depressed patients have high levels of tryptophan metabolites in their urine (Curzon and Bridges, 1970), and a decrease in tryptophan in the blood and cerebrospinal fluid (Maes et al., 1987, 1993). The depletion of tryptophan alone is also associated with a depressed mood (Young et al., 1985). However, this is only apparent in subjects who are at risk of being depressed either because of a family history of depression or because they are in a remission phase (Riedel et al., 2002). Lastly, tryptophan administration in conjunction with an MAO-inhibitor potentiates the antidepressant drug effect (Coppen et al., 1963), which suggests that tryptophan depletion may be a critical biological component of depression.

Tryptophan is mainly metabolized via the kynurenine pathway (Figure 2), beginning with conversion of tryptophan to kynurenine by 1 of 2 enzymes, primarily tryptophan 2,3, dioxygenase or indoleamine 2,3, dioxygenase (IDO). These enzymes are regionally divided in the periphery but are both found in the brain (Saito et al., 1991; Haber et al., 1993; Alberati-giani et al., 1997). Tryptophan 2,3, dioxygenase predominately metabolizes tryptophan in the liver (Nakamura et al., 1980) and responds to hormonal regulations, such as cortisol and glucagon (Nagao et al., 1986; Nakamuras et al., 1987). IDO is found in a variety of tissues, especially immune cells.
IDO activity is induced by the cytokines interferon-gamma and TNF-alpha (Yoshida et al., 1981; Yoshida and Hayaishi, 1987). LPS administration, HIV infection, or interferon treatment increases metabolites of kynurenine in the periphery, brain (Heyes, 1988; Saito et al., 1991), and CSF (Heyes et al., 1989). The first demonstration of a role for IDO activation was in the field of reproductive immunology. Pregnancy is associated with a significant decrease in tryptophan in the plasma (Schröcksnadel et al., 1996), which is secondary to activation of IDO at the level of the trophoblast. Cytotoxic cells that are involved in the recognition of the trophoblast as antigenic become anergic because of the local depletion of tryptophan (Munn et al., 1998). Therefore, it is possible that an increase in IDO following inflammation could deplete tryptophan, resulting in a decreased serotonin concentration in the brain, and cause depressive-like behaviors.

To test this hypothesis, we used the LPS and BCG model of depression to show that activation of IDO is a late event, which is in agreement with the late development of depressive-like behavior. More specifically, we observed that LPS increased IDO in the brain 24 hours after injection (Lestage et al., 2002) at which time depressive-like behavior become apparent (Frenois et al., 2007). This increase in enzymatic activity of IDO was associated with an increase in the ratio of kynurenine to tryptophan in the periphery and brain 24 hours post LPS (O’Connor et al., 2009c; Walker et al., 2013). Other inflammatory agents, including poly I:C and interferon alpha, cause similar behavioral and biochemical results (Gibney et al., 2013; Fischer et al., 2015). Rats injected with poly I:C have elevated IDO and ratio of kynurenine to tryptophan in the brain (Gibney et al., 2013). Similarly, rats administered recombinant human interferon alpha displayed increased immobility in the forced swim test (Fischer et al., 2015). However, their brain ratio of kynurenine to tryptophan was increased but not significantly (P < .10). Imipramine blocked the behavioral effects of interferon but had no effect on the kynurenine to tryptophan ratio. These results are difficult to interpret for several reasons, including the species-specific activity of human interferon alpha. Earlier studies on the behavioral effects of human interferon alpha showed that these are due to activation of brain opioids (e.g., Dafny et al., 1988). Secondly, rats are not a good species for studying IDO activation, because the large quantities of nitric oxide they produce inhibit IDO (Thomas et al., 1994).

To determine if IDO was important, we used pharmacological and genetic tools to demonstrate that activation of this enzyme was necessary for the development of depressive-like behavior, but not sickness behavior. In particular, we found that the IDO inhibitor, 1-methyl tryptophan, blocked the depressive-like behavior but did not significantly alter inflammation or sickness behaviors (O’Connor et al., 2009c). In a similar manner, deletion of the gene coding for IDO, ido1, abrogated the development of BCG-induced depression-like behavior (O’Connor et al., 2009a). After demonstrating that IDO is necessary for the development of depression in our model, the next logical question was whether serotonin depletion was ultimately responsible for the alteration in behavior. However, there was no evidence of a decrease in serotonin levels or serotonin turnover in the brain in response to inflammatory mediators. LPS resulted in an increase, not a decrease, in serotonin turnover (O’Connor et al., 2009c), and similar results have been obtained in models using Poly I:C in rats (Gibney et al., 2013). This ultimately indicates that IDO was altering behavior through another mechanism in this model. The effect of LPS on serotonin levels has not been universal, with some papers reporting a decrease in serotonin following LPS at similar time points (Ji et al., 2014; Yeh et al., 2015). These differences may be due to region of analysis, as O’Connor et al. (2009c) examined whole brain, whereas others report differences in specific regions, including the nucleus accumbens (Yeh et al., 2015) and prefrontal cortex (Ji et al., 2014). It is also possible that different strains of mice may produce different results, as strains vary in serotonin levels at baseline and in response to stress (Shanks et al., 1991).

**Kynurenine Metabolites**

The majority of kynurenine found in the brain during inflammation comes from the periphery (Gál and Sherman, 1980; Kita et al., 2002). It is transported into the brain via the L-type amino acid transporter, also known as solute carrier family 7. Once within the brain, kynurenine produces a variety of neuroactive metabolites, including quinolinic acid and kynurenic acid. Both quinolinic acid and kynurenic acid act at the level of the NMDA receptors, but in opposing directions. Kynurenic acid is an antagonist of the NMDA receptors (but evidence also suggest...
it binds to acetylcholine nicotinic receptors) and decreases glutamate release in the brain (Birch et al., 1988). Quinolinic acid is an agonist of the NMDA receptor (Stone and Perkins, 1981), which can cause excitotoxicity and significant damage to neurons (Foster et al., 1983; Schwarcz et al., 1983; Amori et al., 2009). These 2 metabolites are produced in different cell types in the brain, with quinolinic acid primarily produced in microglia in a kynurenine monooxygenase (KMO)-dependent pathway (Espey et al., 1997) and kynurenic acid produced in astrocytes in a kynurenine aminotransferase-dependent pathway (Guidetti et al., 2007).

With our previous data demonstrating that serotonin was not depleted in our model, we hypothesized that the elevations in kynurenine metabolites could contribute to depressive-like behaviors. Indeed, LPS administration caused an elevation in quinolinic acid but not kynurenic acid in the brain as well as other KMO-dependent kynurenic acid metabolites (Walker et al., 2013). Blockade of quinolinic acid access to NMDA receptors by ketamine was effective at eliminating depressive-like behaviors in LPS-induced depression, but did not alter sickness behaviors or inflammation due to LPS (Walker et al., 2013). Ketamine did not alter IDO activity itself either, which suggests depressive behaviors are due to the overactivation of the NMDA receptor, which could be modulated by quinolinic acid. Walker et al. (2013) also reported elevations in another potentially harmful metabolite, 3-hydroxykynurenine (3HK). 3HK is known to be neurotoxic (Okuda et al., 1996), causes mitochondrial dysfunction (Reyes-Ocampo et al., 2015), and elevates reactive oxygen species (Shoki et al., 1998; Jeong et al., 2004). While 3HK itself may alter behavior through neurotoxic effects, it can cause substantially more damage in the presence of quinolinic acid (Guidetti and Schwarz, 1999). So it is possible that both of these metabolites work in concert to alter neuronal functioning and change behavior.

The clinical literature also reports significant changes in kynurenine pathway metabolites in depressed patients. For example, the ratio of kynurenic acid to quinolinic acid was significantly reduced in depressed patients, and this ratio was significantly correlated with both anhedonia (Savitz et al., 2015b) and volume reductions in mood-related brain regions (Savitz et al., 2015a). In addition, patients who attempted suicide have elevated quinolinic acid levels in the CSF compared with healthy controls (Bay-Richter et al., 2014). In humans with traumatic brain injury, there is an increase in IDO and quinolinic acid in the CSF and brains of patients who had a worse recovery (Yan et al., 2015). Adding further evidence to a role for IDO and quinolinic acid in depression, the metabolites of kynurenic acid are elevated in depressed patients in the CSF without any corresponding change in CSF tryptophan (Raison et al., 2010). Other papers have failed to show alterations in kynurenine or its metabolites in the plasma of depressed patients (Dahl et al., 2015; Meier et al., 2015), and one reported a decrease in plasma kynurenine levels (Hennings et al., 2013). While Meier et al. (2015) did not see changes in kynurenine, they did report that depressed patients have altered kynurenine acid/quinolinic acid and kynurenic acid/3HK ratios. These differences, though, were no longer significant after controlling for sex. Upon examination of their data, they report that differences in males were driving the significant effects, suggesting that sex may be a contributing factor. Another possible explanation for the negative findings is that only a subpopulation of patients may show elevated kynurenine levels. This corresponds well with the data reporting only a portion of depressed individuals have elevated pro-inflammatory cytokines (as discussed above). Likewise, plasma kynurenine levels were increased in individuals who attempted suicide compared with healthy controls and other patients with depression (who had not attempted suicide), so severity of depression may be relevant (Sublette et al., 2011). It is important to note that kynurenine data need to be interpreted with caution, since they do not necessarily reflect ongoing low-grade inflammation. Cortisol-driven activation of the liver enzyme tryptophan 2,3 dioxygenase can also lead to marked elevations in circulating kynurenine. The best way to distinguish inflammation-driven elevations of kynurenine from other causes would be to measure the levels of neopterin, or other markers of immune activation, which is never done (Wildner et al., 2002).

It is also important to mention that mechanisms other than the kynurenine metabolites are being investigated in the inflammation-induced depression model, including brain derived neurotrophic factor (Zhang et al., 2014), leptin (Kurosawa et al., 2015), glucocorticoids (Adzic et al., 2015), and alterations in neurotransmitters, such as adrenaline/noradrenaline (Sekio and Seki et al., 2014; Zhu et al., 2015), dopamine (Yeh et al., 2015), and acetylcholine (Ming et al., 2015).

Clinical Implications: Pharmacological Targets beyond Inflammation

Inflammation is at the origin of the biological cascade that causes depressive behaviors, but it may not always be possible or reasonable to treat inflammation. By exploring downstream mechanisms, it is possible to uncover novel targets for antidepressant therapies (Figure 3). So far, a number of possible targets have been uncovered, including kynurenine metabolites and enzymes, blood-brain barrier transport mechanisms, and glutamatergic neurotransmission. Note all of these targets are working under the assumption that inflammation-induced depression is due to kynurenine metabolites, specifically quinolinic acid, that act on glutamatergic neurons in the brain.

Directly targeting kynurenine production and therefore decreasing its downstream neurotoxic metabolites is one potential avenue for treatment. The most direct method would be to prevent kynurenine accumulation by blocking IDO activity with an inhibitor of the enzyme. Currently, 3 IDO inhibitors, D1-MT, INCB024360, and GDC-0919 (formerly NLC-919), are being tested in patients with solid tumors to suppress immunotolerance of the tumor and enhance response to cancer therapy (Table 1). The specificity of action on IDO1 varies between the drugs (Li et al., 2010). INCB024360 has high specificity for IDO1 (Li et al., 2010), while D-1MT has broader effects (for review, see Lob et al., 2009 and Moon et al., 2015). These clinical trials will give insight into the feasibility of administering IDO inhibitors in the long term, which, if successful, could be considered as possible therapeutics in specific populations of depressed patients. It may also be possible to target other enzymes, such as KMO. KMO catalyzes kynurenine into 3-HK and can be used to create quinolinic acid in microglia cells. Recently, KMO inhibitors have been proposed as potential therapeutic targets for Huntington’s disease (Toledo-Sherman et al., 2015), and it may be worthwhile to explore these molecules in inflammation-induced depression. Kynurenine can alternatively produce kynurenic acid if it is metabolized by KATs instead of KMO, and because kynurenic acid has opposing roles of quinolinic acid, it could counteract its effects. Indeed, studies have demonstrated that administering nicotinylalanine will increase kynurenic acid and have a protective effect on neurons (Russi et al., 1992). Another potential mechanism to modulate the kynurenine metabolism pathway is aerobic exercise. There is already evidence of antidepressant effect of
exercise in rodents (Duman et al., 2008; Marais et al., 2009; Patki et al., 2014) and humans (Silveira et al., 2013). Overexpression of peroxisome proliferator-activated coactivator 1α, a protein elevated in skeletal muscle after exercise, made mice resistant to stress-induced depression by enhancing the enzymatic activity of kynurenine amino transferases and increasing production of the neuroprotective kynurenine metabolite kynurenic acid (Agudelo et al., 2014).

The majority of kynurenine in the central nervous system is transported from the periphery. This transport is mediated through L-type amino acid transporter (Fukui et al., 1991). Tryptophan, kynurenine, and other large neutral amino acids, such as leucine, compete at the transporter for entry into the brain. Recent data from our laboratory indicate that it is possible to block depressive-like behaviors following LPS injection with the amino acid L-leucine. It is hypothesized that leucine would outcompete kynurenine for transport into the brain and thus decrease central kynurenine levels. This does seem to be the case, as our preliminary findings demonstrate that there is a significant reduction in the ratio of kynurenine to tryptophan of the brain in leucine-treated rodents who were administered LPS (Walker et al., 2015). These data indicate that blood-brain transport mechanisms are a viable target for antidepressant treatment.

Excessive levels of glutamate are excitotoxic to neurons (Lucas and Newhouse, 1957), and glutamate dysfunction is a possible cause of depression (for review, see Paul and Skolnick, 2003; Sanacora et al., 2012). In both the LPS-induced and stress-based models of depression, ketamine, an NMDA antagonist, can block depressive-like behaviors (Li et al., 2011; Walker et al., 2013). Targeting glutamate activity can be done by enhancing glutamate reuptake or decreasing glutamate release by facilitating GABA or other molecules that can decrease glutamatergic activity. Astrocytes play an important role in the uptake of glutamate, which helps limit and prevent damage due to excitotoxicity. Astrocytes uptake glutamate through transporters and convert glutamate into glutamine, which can then be released back into the extracellular space and picked up by neurons. Microglia can also take up glutamate from the environment, but, importantly, upon immune activation microglia will release glutamate, which may contribute to excitotoxicity (Takahama et al., 2012; Thomas et al., 2014). A variety of factors, including LPS or TNF, can increase glutamate release from microglia (Thomas et al., 2014), and glutamate exits through two systems in microglia. The first is through the cell adhesion hemichannel (Takeuchi et al., 2006), and the other is System Xc−, the glutamate/cysteine antiporter (Piani and Fontana, 1994; Kigerl et al., 2012). In addition, microglial release of glutamate decreases astrocytes' ability to uptake glutamate, which results in greater neuronal damage (Takahama et al., 2012). In addition, LPS alone can cause glutamate efflux from astrocytes through the release of ATP (Pascual et al., 2012). Likewise, quinolinic acid can prevent the uptake of glutamate by astrocytes through a decrease in the glutamate transporter (Tavares et al., 2002). There is an indication that both...
the release of glutamate from microglia and the modulation of astrocytes due to LPS can be reversed when treated with antagonists of 1 of the 2 transporters that microglia use to export glutamate (Domercq et al., 2007; Takeuchi et al., 2008). Riluzole is a drug used to treat amyotrophic lateral sclerosis. It enhances the expression of glutamate transporters on astrocytes (Carbone et al., 2012), resulting in increased astrocytic glutamate uptake in rats (Frizzos et al., 2004; Yoshizumi et al., 2012), and decreases glutamate release from neurons (Wang et al., 2004). Riluzole has antidepressant effects as determined by the forced swim test (Gourley et al., 2012) and can reverse depression due to chronic stress in rodents (Banerjee et al., 2010). Indeed, riluzole has been tested humans with depression with promising results (Zarate et al., 2005; Sanacora et al., 2007; Ibrahim et al., 2012; Brennan et al., 2010). This drug could be worth investigating in inflammation-induced depression. Overall, targeting the glutamate transport systems within microglia and astrocytes could be another viable method to eliminate depressive-like behaviors.

### Final Remarks

Depression is a debilitating and recurring disorder that is estimated to affect nearly 20% of the population. The most common antidepressant therapies are oral medications that show variable response rates and take weeks to improve the moods of patients. The current medications therefore still have much room for improvement. While antiinflammatory agents have been tested as antidepressants, with some success in special populations of patients, targeting a more specific mechanism could have a greater response rate and be applicable to a wider range of patients. The inflammation-induced model of depression has uncovered the tryptophan-kynurenine pathway as critical for depression, and it has provided a variety of new targets for antidepressant therapies. With further analysis of these downstream pathways, it is possible to also discover mechanisms that are more broadly applicable to other models of depression.

### Acknowledgments

The work reported in this publication was supported by The University of Texas MD Anderson Cancer Center and the National Institutes of Health MD Anderson Cancer Center Support Grant (CA016672) and the National Institute of Mental Health (MH104694). The authors of this publication are responsible for the content, and this publication does not represent the official views of the funding sources.

### Statement of Interest

None.

### References

Adzic M, Djordjevic J, Mitic M, Brkic Z, Lukic I, Radojcic M (2015) The contribution of hypothalamic neuroendocrine, neuroplastic and neuroinflammatory processes to lipopolysaccharide-induced depressive-like behaviour in female and male rats: involvement of glucocorticoid receptor and C / EBP. Behav Brain Res 291:130–139.

Agudelo LZ, Femenia T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V, Correia JC, Izadi M, Bhat M, Schuppe-Koistinen I, Pettersson AT, Ferriera DMS, Krook A, Barres R, Zeirath JR, Erhardt S, Lindskog M, Ruas J (2014) Skeletal muscle PGC-1 a 1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159:33–45.

Alberati-Giani D, Malherbe P, Ricciardi-Castagnoli P, Kohler C (1997) Differential regulation of indoleamine 2,3-dioxigenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglia cells. J Immunol 159:419–426.
Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R (2009) On the relationship between the two branches of the kynurenine pathway in the brain in vivo. J Neurochem 109:316–325.

An L, Li J, Yu S-T, Xue R, Yu N-J, Chen H-X, Zhang L-M, Zhao N, Li Y-F, Zhang Y-Z (2015) Effects of the total flavonoid extract of Xiaobuxin-Tang on depression-like behavior induced by lipopolysaccharide and proinflammatory cytokine levels in mice. J Ethnopharmacol 163:83–87.

André C, O’Connor JC, Kelley KW, Lestage J, Dantzer R, Castanon N (2008) Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3-dioxygenase in response to peripheral lipopolysaccharide administration. J Neuroimmunol 200:90–99.

Armitage R (2007) Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand 115:104–115.

Baganz NL, Lindler KM, Zhu CB, Smith JT, Robson MJ, Iwamoto H, Deneris ES, Hewlett WA, Blakely RD (2015) A requirement of serotoninergic p38α mitogen-activated protein kinase for peripheral immune system activation of CNS serotonin uptake and serotonin-linked behaviors. Transl Psychiatry 5:667–678.

Banarş M, Chowdhury G, Terwilliger R, Newton S, Duman R, Behar K, Sanacora G (2010) Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 15:501–511.

Bassi GS, Canashiro A, Santin FM, De Souza GP, Nobre MJ, Coimbra NC (2012) Lipopolysaccharide-induced sickness behaviour evaluated in different models of anxiety and innate fear in rats. Basic Clin Pharmacol Toxicol 110:359–369.

Basterzi AD, Aydemir I, Kisa C, Aksaray S, Tuzer V, Yazici K, Bra NC (2012) Lipopolysaccharide-induced sickness behavior in patients with major depression. Hum Psychopharmacol 20:473–476.

Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Träsk L, Bendzin L, Guillemine CJ, Erhardt S, Brundin L (2014) A role for inflammatory metabolites as modulators of the glutamate-N-methyl-d-aspartate receptor in depression and suicidality. Brain, Behav and Immun 43:110–117.

Biggio G, Fadda F, Fanni P, Tagliamonte A, Gessa GL (1974) Rapid depletion of serum tryptophan, brain tryptophan, serotonin and 5-hydroxyindoleacetic acid by tryptophan-free diet. Life Sci 14:1321–1329.

Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 154:85–87.

Bluthe R, Dantzer R, Kelley KW (1992a) Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res 573:318–320.

Bluthe R, Beaudu C, Kelley KW, Dantzer R (1995) Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats. Brain Res 677:171–176.

Bluthe R-M, Crestani F, Kelley KW, Dantzer R (1992b) Mechanisms of behavioral effects of interleukin 1: role of prostaglandins and CRF. Ann New York Acad Sci 650:268–275.

Bluthe R-M, Dantzer R, Kelley KW (1991) Interleukin-1 mediates behavioural but not metabolic effects of tumor necrosis factor α in mice. Eur J Pharmacol 209:281–283.

Bluthe RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW, Dantzer R (1994) Synergy between tumor necrosis factor-alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology 19:197–207.

Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M (2002) Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotoninergic system. J Clin Psychopharmacol 22:86–90.

Breber K, Hayley S, Zacharko R, Merali Z, Anisman H (1999) Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 22:566–580.

Brennan BP, Hudson JI, Jensen JE, Mccarthy J, Roberts JL, Perscot AF, Cohen BM, Pope HG, Renahaw PF, Ongur D (2010) Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 35:834–846.

Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancell RB (2001) Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol 110:585–599.

Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD (2008) Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 63:1022–1029.

Capuron L, Ravaud A (1999) Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state. New Eng J Med 340:1370–1370.

Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R (2002) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7:468–473.

Carbone M, Duty S, Rattray M (2012) Neurochemistry International Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem Int 60:31–38.

Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH (2004) Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord 79:285–289.

Carroll BJ, Martin F, Davies B (1968) Resistance to suppression by dexamethasone of plasma 11-O.H.C.S levels in severe depressive illness. Brit Med J 3:285–287.

Carroll BJ, Curtis GC, Mendels J (1976) Cerebrospinal fluid and plasma free cortisol concentrations in depression. Psychol Med 6:235–244.

Coble A, Mcpartland J, Kupfer J, Spiker G, Neil F (1979) EEG sleep in primary depression. J Affect Disord 1:131–138.

Coppen A, Shaw DM, Farrell JP (1963) Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 16:79–81.

Crabtree GR, Gillis S, Smith KA, Muncak A (1979) Glucocorticoids and immune responses. Arthritis Rheum 22:1246–1256.

Crestani F, Seguy F, Dantzer R (1991) Behavioural effects of peripherally injected interleukin-1: role of prostaglandins. Brain Res 542:330–335.

Curzon G, Bridges P (1970) Tryptophan metabolism in depression. J Neurol Neurosurg Psychiatry 33:698–704.

Dafny N, Lee JR, Dougherty PM (1988) Immune response products alter CNS activity and mood disorders in a large animal model. J Abnorm Psychol 97:231–239.

Daldahl J, Andreassen OA, Verkerk R, Fredrik U, Sandvik L, Brundin L, Ormstad H (2015) Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers. Psychoneuroendocrinology 56:12–22.

Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A (2008) Elevated Inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65:409–415.
Frenois F, Moreau M, O'Connor J, Lawson M, Micon C, Lestage J, Foster AC, Collins JF, Schwarcz R (1983) On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and their metabolites that parallel the expression of depressive-like behavior. Nat Rev Neurosci 9:46–57.

Demyttenaere K (2005) The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 8:93–105.

Domercq M, Sanchez-Gomez M V, Sherwin C, Etchebarria E, Fern R, Matute C (2007) System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol 178:6549–6556.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanköft KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457.

Duman CH, Schlesinger L, Russell DS, Duman RS (2008) Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res 9:148–158.

Dunn AJ, Swiergiel AH (2005) Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 81:688–693.

Eisenberger NI, Inagaki TK, Rameson LT, Mashal NM, Irwin MR (2009) NeuroImage An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. NeuroImage 47:881–890.

Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR (2010) Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 68:748–754.

Elgarf AA, Aboul-Foutouh S, Abdel-alkhalek HA, El M, Hassan AN, Kassim SK, Hammouda GA, Farrag KA, Abdel-Tawab AM (2014) Lipopolysaccharide repeated challenge followed by chronic mild stress protocol induces a combined model of depression in rats: reversibility by imipramine and pentoxifylline. Pharmacol Biochem Behav 126:152–162.

Espey MG, Chernyshov ON, Reinhard JF, Nanbuddiri MA, Colton CA (1997) Activated human microglia produce the excitotoxin quinolinic acid. Neuropeptides 8:431–434.

Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A (2008) Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 159:704–710.

Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229.

Ferreira Mello BS, Monte AS, McIntyre RS, Soczynska JK, Custódio CS, Cordeiro RC, Chaves JH, Mendes Vasconcelos SM, Nobre Júnior HV, Florenço de Sousa FC, Hyphantis TN, Carvalho AF, Macêdo DS (2013) Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J Psychiatria Res 47:1521–1529.

Fischer CW, Eskelund A, Budac DP, Tillmann S, Liebenberg N, Elving B, Wegener G (2015) Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats. Behav Brain Res 293:166–172.

Foster AC, Collins JF, Schwartz R (1983) On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 22:1331–1342.

Frenois F, Moreau M, O’Connor J, Lawson M, Micon C, Lestage J, Kelley KW, Dantzner R, Castanon N (2007) Lipopolysaccharide induces delayed FosB/ DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 32:516–531.

Dantzer R, Connor JCO, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–57.

Frizzo M, Dall’Onder L, Dlacin K, Souza D (2004) Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 24:123–128.

Fukui S, Schwarz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017.

Furtado M, Katzman MA (2015) Examining the role of neuroinflammation in major depression. Psychiatry Res 229:27–36.

Gál EM, Sherman AD (1980) L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 5:223–239.

Ge L, Liu L, Liu H, Liu S, Xue H, Wang X, Yuan L, Wang Z, Liu D (2015) Resveratrol abrogates lipopolysaccharide-induced depressive-like behavior, neuroinflammatory response, and CREB/BDNF signaling in mice. Eur J Pharmacol 768:49–57.

George L, Blazer D, Hughes D, Fowler N (1989) Social support and the outcome of major depression. Br J Psychiatry 154:478–485.

Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ (2013) Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun 28:170–181.

Gold PW, Chrousos GP (2002) Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH / NE states. Mol Psychiatry 7:254–275.

Goschen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, Yirmiya R (2008) Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13:717–728.

Gourley SL, Espitia JW, Sanacora G, Taylor JR (2012) Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology (Berl) 219:805–814.

Grigoleit J, Kullmann JS, Wolf OT, Hammes F, Wegner A, Jablonowski S, Engler H, Gizewski E, Oberbeck R, Schedlowski M (2011) Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One 6:1–10.

Grippa AJ, Francis J, Beltz TG, Felder RB, Johnson AK (2005) Neuromedecine and cytokine profile of chronic mild stress-induced anhedonia. Physiol Behav 84:697–706.

Guan X, Lin W, Tang M (2015) Comparison of stress-induced and LPS-induced depressive-like behaviors and the alterations of central proinflammatory cytokines mRNA in rats. Psychopharmacology (Berl) 4:113–122.

Guidetti P, Hoffman GE, Melendez-Ferro M, Albuquerque EX, Schwarz R (2007). Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 55: 78–92.

Guidetti P, Schwarz R (1999) 3-Hydroxykynurenine potentiates quinolinic but not NMDA toxicity in the rat striatum. Eur J Neurosci 11:3857–3863.

Haber R, Bessette D, Hulihan-Giblin B, Durcan MJ, Goldman D (1993) Identification of tryptophan 2,3-dioxygenase RNA in the rodent brain. J Neurochem 60:1159–1162.

Harrison NA, Black L, Walker C, Gray MA, Steptoe A, Critchley HD (2009) Inflammation causes mood changes through inflammation in major depression. Psychiatry Res 229:27–36.

Hart BL (1987) Behavior of sick animals. Vet Clin North Am Food Anim Pract 3:383–391.

Hennings A, Schwarz MJ, Riemer S, Stapf TM, Selberding VB, Rief W (2013) Exercise affects symptom severity but not bio-
logical measures in depression and somatization: results on IL-6, neopterin, tryptophan, kynurenine and 5-HIAA. Psychi- 

try Res 210:925–933.

Henry CJ, Huang T, Wynne A, Hanke M, Himler J, Bailey MT, Sheri- 
dan JF, Godbout JP (2008) Monoamine attenuates lipopolysac- 
charide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 5:15.

Heyes MP (1988) Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electro- 
dynamic technique. J Chromatogr 428:340–344.

Heyes MP, Rubinow D, Lane C, Markey S (1989) Cerebrospinal 
fluid quinolinic acid concentrations are increased in acquired 
immune deficiency syndrome. Ann Neurol 26:275–277.

Hickman RJ, Khambaty T, Stewart JC (2014) C-reactive protein 
is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey 
(NHANES) 1999–2004. J Behav Med 37:621–629.

Howren MB, Lamkin DM, Suls J (2009) Associations of depression 
with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171–186.

Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter 
ID, Kronström P, Moaaddel B, Wainer I, Luckenbaugh DA, Manji 
HK, Zarate CA (2012) Course of improvement in depressive 
symptoms to a single intravenous infusion of ketamine vs ad- 
on-riluzole: results from a 4-week, double-blind, placebo- 
controlled study. Neuropsychopharmacology 17:3526–1533.

Jeong JH, Kim HJ, Lee TJ, Kim MK, Park ES, Choi BS (2004) Epigal- 
locatechin 3-gallate attenuates neuronal damage induced by 3-hydroxykynurenine. Toxicology 195:53–60.

Ji WW, Wang SY, Ma ZQ, Li RP, Li SS, Xue JS, Li W, Niu XX, Yan L, 
Zhang X, Fu Q, Qu R, Ma SP (2014) Effects of perillaldehyde on 
alternations in serum cytokines and depressive-like behavior 
in mice after lipopolysaccharide administration. Pharmacol 
Biochem Behav 116:1–8.

Karlovic D, Serretti A, Vrki N, Martinac M, Mar D (2012) Serum 
concentrations of CRP, IL-6, TNF-α and cortisol in major 
depressive disorder with melancholic or atypical features. 
Psychiatrie Res 198:74–80.

Kent S, Bluthe R, Dantzner R, Hardwickt AJ, Kelleyt KW, Rothwellt 
NJ, Vannice JL (1992) Different receptor mechanisms mediate 
the pyrogenic and behavioral effects of interleukin 1. Proc 
Natl Acad Sci 89:9117–9120.

Kigerl KA, Ankeny DP, Garg SK, Wei P, Guan Z, Lai W, McTigue 
DM, Banerjee R, Popovich PG (2012) System x c - regulates 
microglia and macrophage glutamate excitotoxicity in vivo. 
Exp Neurol 233:333–341.

Kim Y-K, Lee S-W, Kim S-H, Shim S-H, Han S-W, Choi S-H, Lee 
B-H (2008) Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog 
Neuro-Psychopharmacology Biol Psychiatry 32:356–361.

Kita T, Morrison PF, Heyes MP, Markey SP (2002) Effects of sys- 
temic and central nervous system localized inflammation on 
the contributions of metabolic precursors to the L-kynure- 
nine and quinolinic acid pools in brain. J Neurochem:258–268.

Koo JW, Duman RS (2008) IL-1beta is an essential mediator of 
the antineurogenic and anhedonic effects of stress. Proc Natl 
Acad Sci U S A 105:751–756.

Kraus MR, Schäfer A, Faller H, Czeif H, Scheurlem M (2002) Paroxe- 
tine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 16:1091–1099.

Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, 
Baratta MV, Maier SF, Yirmiya R (2014) Dynamic microglial 
alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry 19:699–709.

Kronfol Z, House JD (1989) Lymphocyte mitogenesis, immuno-
globulin and complement levels in depressed patients and normal controls. Acta Psychiatr Scand 80:142–147.

Kronfol Z, House JD, Silva J, Greden J, Carroll BJ (1986) Depression, 
urinary free cortisol excretion and lymphocyte function. Br J 
Psychiatry 148:70–73.

Kubera M, Curzytek K, Duda W, Leskiewicz M, Basta-Kaim A, 
Budziszewska B, Roman A, Zajcova A, Holan V, Szczesny E, 
Lason W, Maes M (2013) A new animal model of (chronic) 
depression induced by repeated and intermittent lipopolysac-
charide administration for 4 months. Brain Behav Immun 
31:96–104.

Kurosawa N, Shimizu K, Seki K (2015) The development of depres-
sion-like behavior is consolidated by IL-6-induced activation 
of locus coeruleus neurons and IL-1 β-induced elevated leptin 
levels in mice. Psychopharmacology (Berl) 239:1725–1737.

Lamers F, Vogelzangs N, Merikangas KR, De Jonge P, Beekman ATT, 
Penninx B (2013) Evidence for a differential role of HPA-axis 
function, inflammation and metabolic syndrome in melan-
cholic versus atypical depression. Mol Psychiatry 18:692–699.

Lasselin, J, Eisenbruch S, Lekander M, Axelsson J, Karshikoff B, 
Grigoleit J, Engler H, Scheldewiers M, Benson S (2016) Mood 
disturbance during experimental endotoxemia: predictors of 
state anxiety as a psychological component of sickness 
behavior. Brain Behav Immun. Advance online publication: 
doi: 10.1016/j.bbi.2016.01.003.

Layes S, Gheusi G, Cremona S, Combe C, Kelley K, Dantzner R, Par- 
et P (2000) Endogenous brain IL-1 mediates LPS-induced 
aneuraxia and hypothalamic cytokine expression. Am J Physiol 
Regul Integr Comp Physiol 279:93–98.

Lestage J, Verrier D, Palin K, Dantzner R (2002) The enzyme 
dioleamine 2,3-dioxygenase is induced in the mouse brain 
in response to peripheral administration of lipopolysaccha-
ride and superantigen. Brain Behav Immun 16:596–601.

Li N, Liu BJ, Dywer YM, Banasr M, Lee B, Son H, Li XY, Aghajanian 
G, Duman RS (2011) Glutamate N-methyl-D-aspartate recep-
tor antagonists rapidly reverse behavioral and synaptic 
deficits caused by chronic stress exposure. Biol Psychiatry 
69:754–761.

Li R, Zhao D, Qu R, Fu Q, Ma S (2015) The effects of apigenin on lipopolysaccharide-induced depressive-like behavior in mice. 
Neurosci Lett 594:17–22.

Liu X et al. (2010) Selective inhibition of IDO1 effectively regu-
lates mediators of antitumor immunity. Blood 115:3520–3531.

Löb S, Königsrainer A, Rammensee H, Opelz G, Terness P (2009) 
Inhibitors of indoleamine-2, 3- dioxygenase for cancer ther- 
apy: can we see the wood for the trees? Nat Rev Cancer 9:445– 
452.

Lotrich FE (2015) Inflammatory cytokine-associated depression. 
Brain Res 1617:113–125.

Lucas DR, Newhouse JP (1957) The toxic effect of sodium L-gluta-
tate on the inner layers of the retina. AMA Arch Ophthalmol 
58: 193–201.

Ma M, Ren Q, Zhang JC, Hashimoto K (2014) Effects of brilliant 
blue G on serum tumor necrosis factor-α levels and depres-
sion-like behavior in mice after lipopolysaccharide adminis-
tration. Clin Psychopharmacol Neurosci 12:31–36.

Maes M (1995) Evidence for an immune response in major 
depression: a review and hypothesis. Prog Neuro-Psychophar-
macol Biol Psychiatr 19:11–38.

Maes M, Van der Planken M, Stevens WJ, Peeters D, Declerck LS, 
Bridts CH, Schotte C, Cosyns P (1992) Leukocytosis, monocy-
tosis, and neutrophilia: hallmarks of severe depression. J Psy-
chiatry Res 26:125–134.
Maes M, Meltzer H, Scharpe S, Bosmans E, Suy E, De Meester I, Calabrese J, Cosyns P (1993) Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 49:151–165.

Maes MHJ, De Ruyter M, Suy E (1987) Prediction of subtype and severity of depression by means of dexamethasone suppression test, L-tryptophan: competing amino acid ratio, and MHPG flow. Biol Psychiatry 22:177–188.

Makino M, Kitano Y, Komiyama C, Takasuna K (2000) Human interferon-α increases immobility in the forced swimming test in rats. Psychopharmacology (Berl) 148:106–110.

Marais I, Stein DJ, Daniels WMU (2009) Exercise increases BDNF levels in the striatum and decreases depressive-like behavior in chronically stressed rats. Metab Brain Dis 24:587–597.

Meier TB, Drevets WC, Wurfel BE, Ford BN, Morris HM, Victor TA, Bodurka J, Teague TK, Dantzer R, Savitz J (2015) Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain Behav Immun. Advance online publication: doi: 10.1016/j.bbi.2015.11.003.

Ming Z, Sawicki G, Bekar LK (2015) Acute systemic LPS-mediated inflammation induces lasting changes in mouse cortical neuroendocytology and behavior. Neurosci Lett 590:96–100.

Moon YW, Hajar J, Hwu P, Naing A (2015) Targeting the indoleamine 2, 3-dioxygenase pathway in cancer. J Immunother Cancer 3:1–10.

Morris AA, Zhao L, Ahmed Y, Stoyanova N, De Staercke C, Hooper WC, Gibbons G, Din-Dzietham R, Quyummy A, Vaccario V (2014) Association between depression and inflammation-differences by race and sex: the META-Health study. Psychosom Med 76:462–468.

Munn DH, Zhou M, Atwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–1193.

Nadjar A, Bluthe R, May MJ, Dantzer R, Parnet P (2005) Inactivation of the cerebral NFκB pathway inhibits interleukin-1β-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 30:1492–1499.

Nagao M, Nakamura T, Ichihara A (1986) Developmental control of gene expression of tryptophan 2, 3-dioxygenase in neonatal rat liver. Biochem Biophys Acta 867:179–186.

Nakamura T, Shinno H, Ichihara A (1980) Insulin and glucagon as a new regulator system for tryptophan oxygenase activity demonstrated in, J Biol Chem 255:7533–7535.

Nakamuras T, Niimis S, Nawas K, Takagit Y, Nakamura T, Shinno H, Ichihara A (1989) Reduced natural killer cell activity as a new regulator system for tryptophan catabolism. J Biol Chem 262:727–733.

Nerozzi D, Santoni A, Bersani IG, Magnani S, Bressan A, Pasini A, Antonot I, Frajese G (1989) Reduced natural killer cell activity in major depression: neuroendocrine implications. Psychoneuroendocrinology 14:295–1989.

Nadal J, Escamilla P, Tello I, García M, Nunez A, Monreal N (2009) The role of the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 3:1–10.

Napoli S, Reichenberg A, Gorman JM, Dieterich DT (2005) Interferon-γ dysregulates IFN-α/β receptor expression in lymphocytes from patients with major depressive disorder. J Neuroimmunol 125:5–14.

Napo M, Meltzer H, Scharpe S, Bosmans E, De Meester I, Calabrese J, Cosyns P (1993) Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 49:151–165.

Napoli S, Reichenberg A, Gorman JM, Dieterich DT (2005) Interferon-γ dysregulates IFN-α/β receptor expression in lymphocytes from patients with major depressive disorder. J Neuroimmunol 125:5–14.

Napo M, Meltzer H, Scharpe S, Bosmans E, De Meester I, Calabrese J, Cosyns P (1993) Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 49:151–165.
Riedel WJ, Klaassen T, Schmitt JAJ (2002) Tryptophan, mood, and cognitive function. Brain Behav Immun 16:581–589.
Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H (2003) Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 251:90–97.
Russi F, Alessiani M, Lombardi G, Davolio P, Pellicciari R, Moroni F (1992) Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J Neurochem 59:2076–2080.
Saito K, Lackner A, Markey SP, Heyes MP (1991) Cerebral cortex and lung indoleamine-2,3-dioxygenase activity is increased in type-D retrovirus infected macaques. Brain Res 540:353–356.
Salazar A, Gonzalez-rivera Bl, Redus L, Parrott JM, Connor JCO (2012) Indoleamine 2, 3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm Behav 62:202–209.
Sanacora G, Kendall SF, Levin Y, Simon AA, Fenton LR, Coric V, Krystal JH (2007) Preliminary evidence ofriluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61:822–825.
Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression. Neuropharmacology 62:63–77.
Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS, Bodurka J, Teague TK, Dantzer R (2015a) Putative neuroprotective and neurotoxic kynurenic pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 40:463–471.
Savitz J, Drevets WC, Wurfel BE, Ford BN, Bellgowan PSF, Victor TA, Bodurka J, Teague TK, Dantzer R (2015b) Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun 52:120–131.
Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M (1984) Lymphocyte function in major depressive disorder. Arch Gen Psychiatry 41:484–486.
Schroöcksnadel H, Baier-Bitterlich G, Dapunt O, Wachter H, Fuchs D (1996) Decreased plasma cryptophan in pregnancy. Obstet Gynaecol 88:47–50.
Schwarz R, Whetsell WO, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219:316–318.
Seidel A, Arolt V, Huntsberger M, Rink L, Behnisch A, Kirchner H (1996) Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol 78:83–85.
Sekio K, Seki K (2014) Lipopolysaccharide-Induced depressive-like behavior is associated with α 1 -adrenoceptor dependent downregulation of the membrane GluR1 subunit in the mouse medial prefrontal cortex and ventral tegmental area. Int J Neuropsychopharmacol:1–12.
Shanks N, Zalcman S, Zacharko R, Anisman H (1991) Alterations of central norepinephrine, dopamine and serotonin in several strains of mice following acute stressor exposure. Pharmacol Biochem Behav 38:69–75.
Shelton R, Claiborne J (2010) Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Molecular 16:751–762.
Sherdell L, Waugh CE, Gotlib IH (2012) Anticipatory pleasure predicts motivation for reward in major depression. J Abnorm Psychol 121:51–60.
Shoki O, Nobuyoshi N, Hiroshi S, Hiroshi K (1998) 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem 70:299–307.
Silveira H, Moraes H, Oliveira N, Coutinho ESF, Laks J, Deslandes A (2013) Physical exercise and clinically depressed patients: a systematic review and meta-analysis. Neuropsychobiology 67:61–68.
Smith RS (1991) The macrophage theory of depression. Med Hypotheses 1:298–306.
Sriram C, Jangra A, Singh S, Mohan P, Kumar B (2016) Physiology and behavior edaravone abrogates LPS-induced behavioral anomalies, neuroinflammation and PARP-1. Physiol Behav 154:135–144.
Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411–412.
Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oguedo MA, John Mann J, Postolache TT (2011) Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 25:1272–1278.
Sulakhiya K, Pratik G, Bezarbaruah BB, Dwivedi S, Gurjar SS, Munde N, Jangra A, Lahkar M, Gogoi R (2016) Lipopolysaccharide induced anxiety- and depressive-like behaviour in mice are prevented by chronic pre-treatment of esculetin. Neurosci Lett 611:106–111.
Takaki J, Fujiwara K, Miura M, Suzuki T, Sekino Y, Sato K (2012) L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the “collusion” hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. J Neuroinflammation 9:275.
Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006) Tumor necrosis factor- induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 281:21362–21368.
Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, Kawanokuchi J, Mizuno T, Sawada M, Suzumura A (2008) Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol 214:144–146.
Tavares RG, Tasca CI, Santos CES, Alves LB, Portíncula LO, Emanueli T, Souza DO (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621–627.
Thomas AG, O’Driscoll CM, Bressler J, Kaufmann W, Rojas CJ, Slusher BS (2014) Small molecule glutaminase inhibitors block glutamate release from stimulated microglia. Biochem Biophys Res Commun 443:32–36.
Thomas SR, Mohr D, Stocker R (1994) Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-γ primed mononuclear phagocytes. J Biol Chem 269:14457–14464.
Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, Brown CJ, Cardaun I, Courtney SM, Dijkman U, Hamelin-Flegg E, Johnson PD, Kempf V, Lyons K, Matthews K, Mitchell WL, O’Connell C, Pena P, Powell K, Rassoulpour A, Reed L, Reindl W, Selvaratnam S, Friley WW, Weddell DA, Went NE, Wheeler P, Winkler C, Winkler D, Wityak J, Yarnold CJ, Yates D, Munoz-Sanjuan I, Domínguez C (2015) Development of a series of aryl pyrimidine kynurenine monoxygenase inhibitors as potential therapeutic agents for the treatment of Huntington’s Disease. J Med Chem 58:1159–1183.
Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR (2012) A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS-stimulated microglia. Brain Behav Immun 26:469–479.

Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29–35.

Vaccarino V, Brennan ML, Miller AH, Bremner JD, Ritchie JC, Lindau T, Veledar E, Su S, Murrah NV, Jones L, Jawed F, Dai J, Goldberg J, Hazen SL (2008) Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: A twin study. Biol Psychiatry 64:476–483.

Vogelzangs N, Duivis HE, Beekman a TF, Kluit C, Neuteboom J, Hoogendijk W, Smit JH, de Jonge P, Penninx BWJH (2012) Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Tranal Psychiatry 2:79.

Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L, Davenport T, Wakefield D, Hickie I, Lloyd A (2004) Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med 34:1289–1297.

Walker A, Vichaya E, Wing E, Banks W, Dantzler R (2015) Leucine blocks lipopolysaccharide-induced depression-like behavior by interfering with kynurenine influx into the brain. Brain, Behav and, Immun 49:e36.

Walker AK, Budac DP, Kelley KW, Dantzler R, Lee AW, Smith RA, Beenders B (2013) NMDA Receptor blockade by ketamine abrogates lipopolysaccharide-induced depression-like behavior in C57BL/6j mice. Neuropsychopharmacology 38:1609–1616.

Wang S, Wang K, Wang’ W, Jen F (2002) Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125:191–201.

Wang Z, Zhang Q, Yuan L, Wang S, Liu L, Yang X, Li G, Liu D (2014) The effects of curcumin on depressive-like behaviors in mice. Behav Brain Res 274:282–290 Available at: http://dx.doi.org/10.1016/j.bbr.2014.08.018.

Yu Z, Luo C, Zhang W, Chen Y, He J, Zhao Q, Zuo R, Wu Y (2011) Pro- and anti-inflammatory cytokines expression in rat’s brain and spleen exposed to chronic mild stress: involvement in depression. Behav Brain Res 225:135–141.

Young SN, Smith SE, Pihp RO, Ervin FR (1985) Tryptophan deple- tion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173–177.

Zarate CA, Quiroz JA, Singh JR, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psych 57:430–432.

Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (2014) Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 18:1–12.

Zhu L, Wei T, Gao J, Chang X, He H, Miao M (2015) Salidroside attenuates lipopolysaccharide (LS) induced serum cytokines and depressive-like behavior in mice. Neurosci Lett 606:1–6.